Subsequently, GABA binds and activates GABAB receptors to inhibit GSK-3β and enhance β-catenin signaling, stimulating tumor cell proliferation, and inhibiting CD8+ T cell infiltration, leading to anti-PD-1 resistance (171). Here, PDCD1 is linked to neoplasm.